AI주식인사이트AI Stock Insight
D

파로스아이바이오

388870KOSDAQ

39.0 / 100

Reference Date: 2026-10-23

Financial Score7.5 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Rose 5.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Paros AI Bio is a R&D-focused company developing innovative drugs for rare and intractable diseases using its AI-based drug discovery platform, Chemiverse. Its lead pipeline, Lasmotinib (PHI-101), is an acute myeloid leukemia treatment designated as an orphan drug in the US, Korea, and Europe. The company also develops PHI-101-OC, a candidate for recurrent ovarian cancer. The platform enables faster drug development with reduced costs and higher success rates.

Number of Employees

33people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
5.44Industry Average 1.200.0Point

4.5x industry avg (risky)

ROE
-66.12Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
104.48Industry Average 100.002.0Point

Higher than industry avg (caution)

Trend 2023~20251.5 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
0.0 / 3

Avg ▼7.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -49.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 5,850Won52-week high 11,62052-week low 4,310
1-month return4.0Point

1m +5.41% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0